Navigation Links
Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development
Date:2/24/2009

Respected Researcher Provides Extensive Experience In Molecular Diagnostics

SALT LAKE CITY, Feb. 24 /PRNewswire/ -- Axial Biotech, Inc., a company revolutionizing spine care through the development of molecular diagnostic technologies, announced today that Roberto A. Macina, Ph.D., has joined the executive management team as the company's new Vice President of Research and Development. Dr. Macina will report directly to Kenneth Ward, M.D., Chairman and Chief Scientific Officer for Axial Biotech.

"With over thirteen years of extensive professional experience in the fields of molecular biology, genomics, cancer research, and molecular diagnostics, Dr. Macina will be a valuable addition to Axial's management and research and development teams," said Dr. Ward. "Dr. Macina made a major contribution to the development of patent protected diagnostic products with high clinical value at diaDexus, Inc. His experience will greatly benefit Axial, as the company expands the indications for ScoliScore(TM) AIS Prognostic Test, the company's first DNA based assay."

Dr. Macina holds a B.S. degree in Biology and a Ph.D. in Biology from the University of Buenos Aires, Argentina. Dr. Macina completed his Post-Doctoral Fellowship at The Wistar Institute. Previous to joining Axial Biotech, Dr. Macina worked with the molecular diagnostics department at SmithKline Beecham in the discovery and characterization of novel genes differentially expressed in different cancers.

"Dr. Macina's decision to join Axial strengthens our company's position as a major player in the molecular diagnostic arena," said John Climaco, President and CEO. "He is joining our senior management team during a period of significant progress and advancement. I am confident that his experience, talent, and energy will very quickly make him a key factor in achieving rapid and efficient advancement of our promising diagnostic products."

"I am extremely excited and enthusiastic about the opportunity to contribute to the continuous growth of Axial Biotech, and to work with a unique combination of talented scientists teamed with skilled medical professionals and expert business specialists," stated Dr. Macina. "I am looking forward to leading the advancement of Axial Biotech's research and development, as the company moves forward with the commercialization of the ScoliScore prognostic test. Additionally, I anticipate that I will be able to effectively expedite the research and development efforts on Axial's pipeline of technologies and products for spinal disorders applications."

About Axial Biotech

Axial Biotech, Inc. is the leading developer of molecular diagnostics for common spinal diseases and disorders. Axial is accredited by the College of American Pathologists (CAP) and is certified to comply with the Clinical Laboratory Improvement Amendments (CLIA). Founded in 2002, Axial is based in Salt Lake City, Utah.


'/>"/>
SOURCE Axial Biotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Axial Biotech Launches Genetic Test for Adolescent Idiopathic Scoliosis (AIS)
2. Axial Biotech Appoints Retired Roche Diagnostics Executive to Board
3. Axial Biotech appoints new Vice President of Strategic Initiatives
4. Axial Biotech Names New VP of Reimbursement and Regulatory Affairs
5. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
6. DuPont Biotech Stewardship Program Gains External Certification
7. Yongye Biotechnology Announces Preliminary Results for Fiscal Year 2008
8. Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask
9. Yongye Biotechnology to Host Virtual Retail Road Show to Provide Overview of the Company in English and Mandarin
10. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
11. Yongye Biotechnology International to Expand its Network of Branded Stores
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):